The impaired stemness properties and reduced invasive features upon knockdown of G6PC3 and SLC37A4 again confirm their implication in metabolic reprogramming and suggest their potential as future therapeutic targets to mitigate the aggressive behavior of GBM. This evidence concerns the gene SLC37A4 and glioblastoma.